Literature DB >> 1964656

Enhanced secretion of prostaglandin E2 by tissue-fixed macrophages in colonic carcinoma.

W J Maxwell1, D Kelleher, J J Keating, F P Hogan, F J Bloomfield, G S MacDonald, P W Keeling.   

Abstract

Prostaglandin E2 (PGE2) secretion by peripheral blood and tissue-fixed macrophages from patients with colorectal carcinoma was assessed. There was no significant difference between PGE2 production by peripheral blood mononuclear cells between patients with colorectal carcinoma and normal controls. However, secretion of PGE2 by tissue-fixed macrophages from within the colorectal carcinomata in response to opsonised zymosan was significantly higher than in the uninvolved colonic tissue. PGE2 production by tissue-fixed macrophages from within colonic polyps was found to be normal. These results could not be explained on the basis of increased availability of substrate arachidonic acid since addition of excess arachidonic acid resulted in similar findings. The enhanced production of PGE2 correlated with Dukes staging but not the level of differentiation. The production of PGE2 from epithelial cells in response to ionophore A23187 was not significantly enhanced. Leukotriene B4 secretion by intestinal macrophages in response to opsonised zymosan was not significantly elevated in the colonic tumour tissue. Modulation of levels of prostaglandin production within colonic tumours may play a role in the rate of growth and vascularity of these tumours and in the regulation of the local immune response to malignancy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964656     DOI: 10.1159/000200492

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  9 in total

1.  Kupffer cells and pit cells are not effective in the defense against experimentally induced colon carcinoma metastasis in rat liver.

Authors:  P Griffini; S M Smorenburg; I M Vogels; W Tigchelaar; C J Van Noorden
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

Review 2.  Aspirin, NSAIDs, and digestive tract cancers.

Authors:  M J Thun
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

3.  Localization of cyclooxygenase-2 in human sporadic colorectal adenomas.

Authors:  K S Chapple; E J Cartwright; G Hawcroft; A Tisbury; C Bonifer; N Scott; A C Windsor; P J Guillou; A F Markham; P L Coletta; M A Hull
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

4.  Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma.

Authors:  C N Chen; C T Sung; M T Lin; P H Lee; K J Chang
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

5.  Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas.

Authors:  Jian-Gang Jiang; Jiang-Bo Tang; Chun-Lian Chen; Bao-Xing Liu; Xiang-Ning Fu; Zhi-Hui Zhu; Wei Qu; Katherine Cianflone; Michael-P Waalkes; Dao-Wen Wang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

6.  Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.

Authors:  Tae-Ho Kim; Young-Il Jeong; Shu-Guang Jin; Jian Pei; Tae-Young Jung; Kyung-Sub Moon; In-Young Kim; Sam-Suk Kang; Shin Jung
Journal:  Int J Nanomedicine       Date:  2011-10-28

7.  Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?

Authors:  J Ostrowski; T Wocial; H Skurzak; W Bartnik
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

8.  Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines.

Authors:  A Hara; N Yoshimi; M Niwa; N Ino; H Mori
Journal:  Jpn J Cancer Res       Date:  1997-06

9.  Long-term differential changes in mouse intestinal metabolomics after γ and heavy ion radiation exposure.

Authors:  Amrita K Cheema; Shubhankar Suman; Prabhjit Kaur; Rajbir Singh; Albert J Fornace; Kamal Datta
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.